ISLAMABAD - Pharma Bureau Pakistan, the representative body of multinational pharmaceutical companies working in Pakistan, has strongly opposed the drug regulation rules that are against the interests of both consumers and the industry.

In a statement, the spokesperson of the Bureau appealed to the government to simplify the registration of new molecules as years of delays deprive the Pakistani patients from benefiting from newly discovered drugs and breakthrough technologies.

The statement suggested a simple and transparent formula in this regard.

The government should give approval to the drug that has been approved in two of the three developed economies that includes United States, European Union and Japan.

These countries have highly credible regulatory bodies and drugs approved by them to be used by their citizens undergo rigorous clinical trials and other processes which should give our regulators confidence to introduce them in market.

The spokesperson said that pricing is a crucial issue in drug regulation. He said that availability of a drug is vital. A simple pricing formula, he added, should be to reference prices in Pakistan with the price of the same drug in countries in the South Asian region. This, he added, would ensure sustained supplies of drugs at reasonable rates.